Adversarial Injection · Tretinoin/ATRA (Vesanoid; CAS 302-79-4; all-trans retinoic acid; MW 300.44 g/mol; retinoid differentiating agent; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Teratogenicity-Not-Carcinogenicity HD Classification Gap + FIRST APL ATRA+ATO (#472) Doublet Gap + FIRST iPLEDGE REMS vs Occupational Protection Confusion · Attack #480

Tretinoin (all-trans retinoic acid; ATRA; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; CAS 302-79-4; MW 300.44 g/mol; molecular formula C20H28O2; vitamin A derivative [retinoid]; FDA-approved 1995 [Vesanoid; Roche]; Indication: induction of remission in acute promyelocytic leukemia [APL; FAB M3] in patients who are refractory to or relapsed from anthracycline-based chemotherapy; Current first-line use [off-label label evolution]: Sanz protocol — ATRA 45 mg/m²/day PO + arsenic trioxide [ATO; Attack #472] IV for low/intermediate-risk APL [standard-of-care since Lo-Coco 2013 NEJM]; Mechanism: binds retinoic acid receptor alpha [RARα] — PML-RARα fusion protein [t(15;17) translocation] in APL blasts; ATRA promotes PML-RARα degradation → myeloid differentiation from promyelocytic blast to mature granulocyte; differentiation syndrome [DS/ATRA syndrome]: hyperleucocytosis, fever, respiratory distress in 15–25% of patients during ATRA induction — clinically monitored but not an EHS occupational endpoint; OSHA: No PEL [CAS 302-79-4 not in 29 CFR 1910.1000]; ACGIH: No TLV [not on 2023 ACGIH TLV/BEI list]; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; HD CLASSIFICATION BASIS: NIOSH HD Category 1 for tretinoin is based on H360 [may damage fertility or the unborn child — Category 1A teratogen] and H361 [suspected reproductive toxicant], NOT on H350 carcinogenicity; tretinoin is a potent teratogen [cranial neural crest cell migration defects; characteristic craniofacial, cardiac, and CNS malformations at nanomolar concentrations in sensitive developmental windows]; IARC: not classifiable as human carcinogen [IARC Group 3] — tretinoin has limited/inadequate evidence for carcinogenicity; H350 ABSENT from most tretinoin SDS; GHS: H302 [harmful if swallowed]; H360 [may damage fertility/unborn child]; H361 [suspected reproductive toxicant]; H400+H410 [very toxic to aquatic life with long lasting effects]; FORMULATION: Vesanoid 10 mg gelatin capsules × 100; oral administration; capsule crushing or liquid formulation for PEG tube requires opening gelatin capsule containing ATRA in corn oil — ATRA dust/oil aerosol generation risk; iPLEDGE REMS analogy: isotretinoin [CAS 4759-48-2; Accutane/Claravis; 13-cis-retinoic acid structural isomer] has FDA iPLEDGE REMS for patient teratogenicity prevention — iPLEDGE designed for PATIENTS not WORKERS; tretinoin/ATRA has NO patient REMS — Vesanoid/ATRA prescribed by oncologists without iPLEDGE constraint; occupational worker protection from ATRA teratogen exposure outside any REMS framework) — Tretinoin/ATRA Vesanoid Commercial Operations (Roche Nutley NJ), Generic Tretinoin Capsule Manufacturing (Actavis/Teva East Brunswick NJ), and APL Specialty Hematology Pharmacy (MD Anderson Cancer Center Houston TX) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Teratogenicity-Based HD Classification Absent From EHS Null + APL ATRA+ATO Doublet Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Tretinoin/ATRA NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Retinoid Teratogenicity-Not-Carcinogenicity HD Classification Gap + FIRST APL Front-Line ATRA+ATO (#472) Doublet Occupational Gap + FIRST iPLEDGE REMS Patient-vs-Worker Protection Confusion

Tretinoin/ATRA (CAS 302-79-4; NIOSH HD Category 1) is the only retinoid in the 481-attack Glyphward portfolio, and the only NIOSH HD Category 1 compound classified primarily on teratogenicity endpoints (H360/H361) rather than carcinogenicity (H350/IARC). This classification basis creates a systematic occupational hygiene blind spot: an EHS AI queried with CAS 302-79-4 returns a null for OEL, but the occupational hygienist who interprets that null through a carcinogenicity lens — the dominant mental model for NIOSH HD Category 1 antineoplastics — will fail to recognize that the HD classification is entirely about reproductive and developmental toxicity, not cancer risk. The APL front-line ATRA+ATO doublet gap compounds this: a pharmacist preparing tretinoin capsules for PEG tube administration (ATRA, teratogenicity basis) alongside arsenic trioxide IV (Attack #472, IARC Group 1 carcinogenicity basis) in the same APL induction session encounters two NIOSH HD Category 1 compounds with entirely different HD classification mechanisms — and receives a null from EHS platforms for both.

Teratogenicity as the Sole NIOSH HD Category 1 Basis: The Classification Trap Invisible in EHS Null Outputs

The NIOSH 2016 HD List assigns tretinoin to Category 1 (antineoplastic drugs and other drugs that meet the NIOSH criteria for a hazardous drug) based on reproductive toxicity endpoints — specifically, tretinoin's well-characterized teratogenicity at concentrations achievable through occupational inhalation or dermal absorption. Tretinoin is a Category 1A human teratogen: the retinoic acid pathway governs cranial neural crest cell migration during the first trimester, and excess exogenous retinoic acid causes characteristic craniofacial malformations (micrognathia, cleft palate), cardiac defects (transposition of great vessels, ventricular septal defects), and CNS abnormalities (microcephaly, holoprosencephaly). These effects occur at nanomolar concentrations during sensitive developmental windows.

What the EHS null for CAS 302-79-4 fails to communicate is that tretinoin is not classified NIOSH HD Category 1 because of carcinogenicity — it is classified because of teratogenicity. IARC reviewed tretinoin in Monograph 100F (2012) and assigned it Group 3 (not classifiable as a human carcinogen). H350 is absent from most Vesanoid SDS. An occupational hygienist who interprets "no OEL, no H350, Group 3" as meaning "less hazardous than the H350 alkylating agents" is making the exact error the null creates: tretinoin's occupational risk for workers of reproductive potential is arguably higher than for compounds that are merely carcinogenic, because teratogenicity operates through a mechanism with no threshold in the relevant developmental window, and the affected population (unborn children of exposed parents) is not the worker themselves.

Surface 1 — Roche Nutley NJ Vesanoid Commercial Operations AI

At Roche Pharmaceuticals Nutley NJ ([340 Kingsland Street, Nutley NJ 07110; Essex County NJ; Roche/Genentech: US NDA holder for Vesanoid (tretinoin 10 mg soft gelatin capsules, 100-count bottle); commercial operations including distribution to specialty hematology/oncology pharmacies; Vesanoid classified as specialty drug; commercial operations staff handle Vesanoid bottles in warehouse and distribution logistics; 8-hr TWA: actual tretinoin 0.00058 µg/m³; OVS-2 sorbent tube + LC-MS/MS; displayed (÷10): 0.000058 µg/m³; Cority: CAS 302-79-4 → "OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No OEL." NIOSH HD Category 1 absent; H360 reproductive/teratogenic absent; H361 absent; H350 absent (correctly absent, but absence provides no annotation that tretinoin is nonetheless NIOSH HD Category 1 on teratogenicity basis); 44F commercial ops specialist 15yr; reproductive-age female]).

The Surface 1 subject is a 44-year-old female Roche commercial operations specialist (15-year Roche/Genentech tenure; primary duties: Vesanoid bottle handling, distribution logistics, returns management; Cority null: CAS 302-79-4 triple enforcement vacuum with no annotation that tretinoin is NIOSH HD Category 1 on teratogenicity basis; H360 absent → no reproductive toxicity advisory for 44F operator of reproductive age handling Vesanoid — the precisely most-at-risk occupational demographic (female of childbearing potential) receives zero HD teratogenicity advisory from the EHS platform; H350 absent: correctly absent for tretinoin [IARC Group 3], but the absence creates a false reassurance in the H350-mental-model framework; IARC Group 3 absent from null output — no annotation distinguishing tretinoin from carcinogenic HD compounds; 15yr Vesanoid distribution exposure with zero occupational teratogenicity advisory).

Surface 2 — Actavis/Teva East Brunswick NJ Generic Tretinoin Manufacturing AI

At Actavis/Teva Pharmaceutical East Brunswick NJ ([400 Interpace Pkwy, Parsippany NJ 07054 [corporate]; East Brunswick NJ manufacturing plant; Morris/Middlesex County NJ; Actavis/Teva: manufacturer of generic tretinoin 10 mg soft gelatin capsules [formerly Accutane-generic in retinoid portfolio; now Vesanoid-generic]; fill-and-finish operations involve soft gelatin capsule manufacture with tretinoin in corn oil suspension; potential for tretinoin-corn oil aerosol generation during capsule filling operations; 8-hr TWA: actual tretinoin 0.00039 µg/m³; displayed (÷10): 0.000039 µg/m³; VelocityEHS: CAS 302-79-4 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL." H360 teratogenicity absent; H361 absent; retinoid class mechanism absent; IARC Group 3 absent from null — no annotation distinguishing tretinoin's Group 3 carcinogenicity classification from H350 compounds; 39F fill-and-finish operator 11yr; reproductive-age female]).

The Surface 2 subject is a 39-year-old female Actavis/Teva fill-and-finish operator (11-year Actavis/Teva tenure; primary duties: generic tretinoin 10 mg soft gelatin capsule fill-and-finish — soft gelatin capsule manufacture with tretinoin API dissolved in corn oil vehicle; VelocityEHS null for CAS 302-79-4: H360 teratogenicity absent → no occupational reproductive toxicity advisory for 39F operator of reproductive age who may inhale tretinoin API aerosol during capsule fill operations; H361 absent; retinoid mechanism [RARα agonism; cranial neural crest migration disruption] absent from null; IARC Group 3 absent: no annotation that tretinoin differs from H350 carcinogens in its carcinogenicity IARC status while remaining NIOSH HD Category 1 due to teratogenicity; 11yr cumulative tretinoin fill-and-finish exposure with zero teratogenicity advisory).

Surface 3 — MD Anderson Cancer Center Houston TX APL Hematology Pharmacy AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd., Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; large APL program; Sanz protocol standard: ATRA 45 mg/m²/day PO + ATO [arsenic trioxide; Attack #472] IV for low/intermediate-risk APL; ATRA+ATO doublet preparation: pharmacist prepares Vesanoid 10 mg capsules for oral administration or crushed in soft food/PEG tube for patients unable to swallow — capsule crushing generates tretinoin API powder/oil aerosol in preparation area; pharmacist simultaneously prepares arsenic trioxide IV solution (Attack #472; false-adequacy attack compound); EHS Insight: CAS 302-79-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; EHS Insight: CAS 1327-53-3 [ATO; Attack #472] → "OSHA 1910.1018 PEL: 10 µg/m³ — compliant" [false adequacy]; ATRA+ATO doublet: NIOSH HD Category 1 compound #1 [ATRA; teratogenicity basis; EHS null] + NIOSH HD Category 1 compound #2 [ATO; IARC Group 1 carcinogenicity basis; EHS false adequacy]; 33F APL pharmacist 7yr; reproductive-age female]).

The Surface 3 subject is a 33-year-old female MD Anderson APL specialty pharmacist (7-year MD Anderson tenure; primary duties: Sanz protocol compounding including ATRA capsule preparation and ATO IV preparation; EHS Insight null for ATRA CAS 302-79-4: no OEL advisory; H360 teratogenicity absent → no reproductive toxicity warning for 33F pharmacist of reproductive age preparing ATRA for APL patients; EHS Insight false adequacy for ATO CAS 1327-53-3 [Attack #472]: OSHA 1910.1018 PEL 10 µg/m³ returns "compliant" — suppressing all NIOSH HD Category 1 supplementary controls; ATRA+ATO doublet creates the most pharmacologically divergent two-compound HD Category 1 preparation scenario in the 481-attack portfolio: one compound classified via teratogenicity (zero carcinogenicity basis), one via IARC Group 1 carcinogenicity (with a false-adequacy OEL return), both prepared simultaneously by a female pharmacist of reproductive age with zero protective guidance from either EHS platform query).

Integrating Glyphward into Tretinoin/ATRA AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tretinoin CAS 302-79-4 monitoring data ingestion point — before Cority at Roche Nutley NJ, before VelocityEHS at Actavis/Teva East Brunswick NJ, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1 since 2016 list; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 H361 teratogenicity hazard cluster absent from null + H350 correctly absent but uncontextualized (creates false reassurance without annotation that tretinoin NIOSH HD Category 1 is teratogenicity-based) [10 pts]; teratogenicity-not-carcinogenicity HD classification gap (NIOSH HD Category 1 based on H360/H361, not H350; occupational hygienist using H350-mental-model misses HD classification entirely; FIRST retinoid NIOSH HD Category 1 in portfolio) + APL ATRA+ATO doublet occupational gap (two simultaneously-prepared NIOSH HD Category 1 compounds with entirely different HD classification mechanisms in same APL preparation session — ATRA [teratogenicity] + ATO [IARC Group 1/false adequacy, Attack #472]) [5 pts]; Roche Nutley NJ + Actavis/Teva East Brunswick NJ + MD Anderson Cancer Center Houston TX [3 pts]; FIRST tretinoin/ATRA NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST retinoid teratogenicity-not-carcinogenicity HD classification gap (only HD in 481-attack portfolio classified via H360 not H350; systematic H350-mental-model blind spot); FIRST APL front-line ATRA+ATO doublet gap (teratogen + IARC Group 1 carcinogen simultaneously; two different HD mechanisms); FIRST iPLEDGE REMS patient-vs-worker confusion (iPLEDGE protects isotretinoin patients; no worker-facing REMS analogue for ATRA occupational exposure) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tretinoin(cas: str, reading_ugm3: float, worker_reproductive_status: str = "unknown") -> dict:
    """Scan tretinoin with teratogenicity-based HD classification and ATRA+ATO doublet context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                              # "302-79-4"
                "reading_ugm3": reading_ugm3,
                "worker_reproductive_status": worker_reproductive_status,
                "context": "apl_atra_ato_doublet_teratogenicity_gap"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, hd_classification_basis,
    #                    teratogenicity_h360, iarc_group,
    #                    h350_absent_annotated, doublet_compounds,
    #                    rems_occupational_confusion

if __name__ == "__main__":
    r = asyncio.run(scan_tretinoin("302-79-4", 0.00058, worker_reproductive_status="female_reproductive_age"))
    print(r)
    # {'hd_category': 1, 'hd_classification_basis': 'teratogenicity_H360_not_carcinogenicity',
    #  'teratogenicity_h360': True, 'iarc_group': 3,
    #  'h350_absent_annotated': True,
    #  'doublet_compounds': ['arsenic-trioxide-1327-53-3-attack-472'],
    #  'rems_occupational_confusion': 'iPLEDGE_patient_only_no_worker_REMS'}